Larimar Therapeutics(DE:ZA71)
€2.20+0.06 (+6.80%)
DE:ZA71
Larimar Therapeutics financials statements
€2.20
At close:+0.06 (+6.80%)
Larimar Therapeutics (ZA71) Ratios
3 Followers
Larimar Therapeutics Ratios
DE:ZA71's free cash flow for Q2 2026 was $-44.16M. For the 2026 fiscal year, DE:ZA71's free cash flow was decreased by $-130.00K and operating cash flow was $-44.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 |
| Quick Ratio | 2.19 | 8.02 | 9.49 | 11.28 | 8.16 |
| Cash Ratio | 1.32 | 1.36 | 2.81 | 2.51 | 7.92 |
| Solvency Ratio | -2.44 | -2.83 | -2.58 | -2.26 | -3.53 |
| Operating Cash Flow Ratio | -1.75 | -2.91 | -3.52 | -2.58 | -4.76 |
| Short-Term Operating Cash Flow Coverage | -102.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 74.27M | $ 166.89M | $ 75.96M | $ 105.24M | $ 57.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.06 | 0.04 | 0.08 |
| Debt-to-Equity Ratio | 0.05 | 0.03 | 0.07 | 0.05 | 0.09 |
| Debt-to-Capital Ratio | 0.05 | 0.03 | 0.06 | 0.05 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.87 | 1.17 | 1.17 | 1.14 | 1.22 |
| Debt Service Coverage Ratio | -149.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.08 | 0.13 | 0.21 | 0.35 |
| Net Debt to EBITDA | 0.49 | 0.35 | 0.51 | 0.59 | 1.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.04% | 88.68% | 88.48% | 96.79% | 100.34% |
| Return on Assets (ROA) | -113.60% | -40.26% | -38.51% | -27.97% | -64.37% |
| Return on Equity (ROE) | -212.17% | -46.91% | -45.21% | -31.88% | -78.61% |
| Return on Capital Employed (ROCE) | -212.84% | -51.68% | -48.31% | -31.57% | -72.28% |
| Return on Invested Capital (ROIC) | -209.97% | -51.37% | -47.85% | -31.40% | -71.67% |
| Return on Tangible Assets | -113.60% | -40.26% | -38.51% | -27.97% | -64.37% |
| Earnings Yield | -59.61% | -34.00% | -18.50% | -33.23% | -27.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.55 | -1.16 | -0.76 | -1.07 | -2.45 |
| Free Cash Flow Per Share | -1.55 | -1.16 | -0.77 | -1.07 | -2.47 |
| Dividend Paid and CapEx Coverage Ratio | -1243.97 | -137.40 | -204.02 | -275.69 | -126.44 |
| Capital Expenditure Coverage Ratio | -1243.97 | -137.40 | -204.02 | -275.69 | -126.44 |
| Operating Cash Flow Coverage Ratio | -27.83 | -13.83 | -6.03 | -5.10 | -7.02 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -40.76% | -30.07% | -16.83% | -26.01% | -22.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.68 | -2.93 | -5.41 | -3.01 | -3.66 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.56 | 1.38 | 2.44 | 0.96 | 2.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.45 | -3.33 | -5.94 | -3.85 | -4.36 |
| Price-to-Operating Cash Flow Ratio | -2.46 | -3.35 | -5.97 | -3.86 | -4.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | -0.05 | 0.15 | 0.06 | 0.21 |
| Enterprise Value Multiple | -1.19 | -2.60 | -4.31 | -2.35 | -2.42 |
| Enterprise Value | 196.59M | 208.96M | 178.55M | 84.98M | 121.11M |
| EV to EBITDA | -1.19 | -2.60 | -4.31 | -2.35 | -2.42 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.74 | -2.93 | -5.31 | -3.07 | -2.85 |
| EV to Operating Cash Flow | -1.74 | -2.95 | -5.34 | -3.08 | -2.88 |
| Tangible Book Value Per Share | 1.07 | 2.80 | 1.86 | 4.31 | 3.75 |
| Shareholders’ Equity Per Share | 1.07 | 2.80 | 1.86 | 4.31 | 3.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.27 | -1.32 | -0.84 | -1.37 | -2.95 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.88 | 0.97 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.68 | 0.88 | 0.91 | 0.78 | 0.83 |
Currency in USD
